Skip to main content

Table 5 Cox proportional hazards model for regression analysis on risk factors for prognosis of NPC patients

From: Roles of β-catenin, TCF-4, and survivin in nasopharyngeal carcinoma: correlation with clinicopathological features and prognostic significance

Features

B

SE

Wald

Sig.

Exp (B)

95.0% CI for Exp (B)

OS

 Clinicopathological stages

1.508

0.281

28.846

< 0.001

4.517

2.605

7.832

  β-catenin

1.738

0.667

6.787

0.009

5.687

1.538

21.030

  TCF4

1.515

0.619

5.993

0.014

4.548

1.353

15.293

  Survivin

1.499

0.555

7.289

0.007

4.479

1.508

13.300

  EBV-VCA-IgA

2.607

0.779

11.190

0.001

13.562

2.944

62.482

  EBV-EA-IgA

2.476

0.486

25.986

< 0.001

11.890

4.590

30.803

DMFS

 Clinicopathological stages

1.873

0.283

43.663

< 0.001

6.508

3.734

11.343

  β-catenin

2.334

0.753

9.610

0.002

10.321

2.359

45.146

  TCF4

2.145

0.562

14.544

< 0.001

8.538

2.836

25.707

  EBV-EA-IgA

0.766

0.349

4.806

0.028

2.151

1.085

4.268

LRFS

 Family history

1.181

0.282

17.512

< 0.001

3.257

1.873

5.663

 N stage

0.736

0.195

14.232

< 0.001

2.087

1.424

3.058

 Clinicopathological stages

1.230

0.219

31.463

< 0.001

3.421

2.226

5.257

  TCF4

1.754

0.521

11.323

0.001

5.776

2.080

16.041

  EBV DNA

1.393

0.464

9.008

0.003

4.028

1.622

10.004

  EBV-EA-IgA

1.162

0.343

11.497

0.001

3.198

1.633

6.261

DFS

 Clinicopathological stages

1.639

0.203

65.080

< 0.001

5.150

3.458

7.669

  β-catenin

1.232

0.484

6.470

0.011

3.429

1.327

8.863

  TCF4

1.635

0.540

9.163

0.002

5.131

1.780

14.793

  Survivin

1.039

0.464

5.011

0.025

2.826

1.138

7.016

  EBV DNA

1.396

0.351

15.780

< 0.001

4.039

2.028

8.042

  EBV-VCA-IgA

1.467

0.335

19.171

< 0.001

4.336

2.249

8.362

  EBV-EA-IgA

1.239

0.275

20.293

< 0.001

3.452

2.014

5.919

  1. TCF-4 T-cell factor-4, NPC nasopharyngeal carcinoma, T tumor, N node, SE standard error, Sig. significance, 95% CI 95% confidence interval, OS, overall survival; DMFS, distant metastasis-free survival; LRFS, local recurrence-free survival; DFS, disease-free survival